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ABSTRACT
Background
The roll-out of antiretroviral treatment (ART) in developing countries concentrates on finding
patients currently in need, but over time many HIV-infected individuals will be identified who
will require treatment in the future. We investigated the potential influence of alternative
patient management and ART initiation strategies on the impact of ART programmes in sub-
Saharan Africa.
Methods and Findings
We developed a stochastic mathematical model representing disease progression, diagnosis,
clinical monitoring, and survival in a cohort of 1,000 hypothetical HIV-infected individuals in
Africa. If individuals primarily enter ART programmes when symptomatic, the model predicts
that only 25% will start treatment and, on average, 6 life-years will be saved per person treated.
If individuals are recruited to programmes while still healthy and are frequently monitored, and
CD4
þ cell counts are used to help decide when to initiate ART, three times as many are
expected to be treated, and average life-years saved among those treated increases to 15. The
impact of programmes can be improved further by performing a second CD4
þcell count when
the initial value is close to the threshold for starting treatment, maintaining high patient follow-
up rates, and prioritising monitoring the oldest (  35 y) and most immune-suppressed patients
(CD4
þcell count   350). Initiating ART at higher CD4
þcell counts than WHO recommends leads
to more life-years saved, but disproportionately more years spent on ART.
Conclusions
The overall impact of ART programmes will be limited if rates of diagnosis are low and
individuals enter care too late. Frequently monitoring individuals at all stages of HIV infection
and using CD4 cell count information to determine when to start treatment can maximise the
impact of ART.
The Editors’ Summary of this article follows the references.
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For a decade, HIV-infected persons in developed countries
whose clinical course is advancing towards AIDS have been
offered combination antiretroviral therapy (ART); this
practice has generated a sharp decline in the rate of AIDS
deaths [1]. More recently, the humanitarian crisis associated
with the general spread of HIV in many African countries has
led to an unprecedented ﬁnancial and logistical commitment
to providing ART to those in need [2–4]. Activities now focus
on identifying those currently requiring treatment rather
than on how to monitor those with future treatment needs
[5]. However, decisions need to be made about how to care
for all HIV-infected individuals. These decisions will deter-
mine the prognosis when an individual initiates ART, and the
future demand for ART and other health and social services
across the population.
Survival of HIV-infected individuals on ART depends on
the state of their immune system when treatment is begun
[6,7]. Whilst in Western countries the decision to initiate ART
is informed by a range of high-technology tools [8,9], in
poorer countries a more pragmatic public-health approach
has been adopted [10]. The World Health Organisation
(WHO) has recommended using CD4
þ cell counts to decide
when treatment should be initiated [5], but in many settings
the decision to start therapy is made without any laboratory
support, and instead makes use of disease staging criteria [10].
Although early signs of disease can be apparent within a few
years of HIV infection [11,12], advanced immune depletion
and the need for ART are not always associated with
symptoms [13–15].
Whilst a great deal of work has focussed on the optimal
state at which to initiate ART [16–19], the way in which this
process interacts with other aspects of ART delivery to
determine overall efﬁcacy has not received close attention.
Understanding the factors that determine the impact of ART
programmes will help inform best-practice guidelines and
facilitate more accurate projections of future health-care
needs. However, making predictions of the effect of ART at
the population level is complicated by variability between
patients in the rate of disease progression, uncertainty in
CD4
þ cell count measurements, and other stochastic events,
such as unrelated causes of mortality and opportunities for
diagnosing women during pregnancies. In clinical trials, it
would be unethical to compromise patient management and
impossible to compare the full range of alternative manage-
ment strategies. To address these issues, we have developed a
mathematical simulation model that follows a theoretical
cohort of HIV-infected individuals as the disease progresses,
tracking when symptoms occur, how the individual is
monitored, the decision to initiate ART, and the effect ART
has on survival.
Methods
Approach
Our stochastic cohort model represents 1,000 individuals
infected with HIV. Each individual is assigned particular
characteristics (such as the rapidity of immune suppression
and when symptoms occur), and the model calculates when
the individual would be expected to die if he or she did not
have HIV, had HIV but no treatment, or had HIV and
treatment were available. By representing a cohort of
individuals with a range of characteristics, we can estimate
the mean population level outcomes, such as life-years saved
by treatment, and how much variability there is in these
outcomes.
The impact of treatment with different strategies for its
delivery was analysed by running the cohort model under a
variety of assumptions concerning (i) how and when the
infection is diagnosed; (ii) how frequently individuals are
monitored before they start ART and whether they are lost to
follow-up; and (iii) whether CD4
þ counts are used to help
decide when to initiate ART. Since long-term survival on ART
was not known, the simulations were repeated making
different assumptions about this, based on the short-term
observational data that is available [6,7].
Individuals can be diagnosed when they develop symptoms
and present at a clinic, or when they are referred from an
antenatal clinic (ANC), or when they voluntarily get tested for
HIV (voluntary counselling and testing, VCT). For simplicity,
we investigated circumstances that range from the worst-case
to the achievable best-case scenario. We varied the fraction of
women referred from ANC between 10% and 90%, and the
fraction of infected individuals that receive VCT whilst they
are still healthy between 5% and 70%. Various strategies were
designed for monitoring individuals found to be infected but
not yet on ART (Table 1). The scheduled intervals between
appointment were set at 24, 12, 6 or 3 mo, and could be the
same for all patients or vary according to the patient’s age
and/or degree of immune suppression. We assumed that the
fraction of individuals ‘‘lost to follow-up’’ each year at this
stage varies between 15% and 0%. Different decision rules
for initiating ART were also incorporated in the model (Table
2). With these different rules, the inﬂuence of ART being
initiated with and without CD4
þ cell counts, or with different
CD4
þ cell count thresholds, was investigated.
Our analysis had three parts. First, we compared individual
and population outcomes when there is no ART with the
situation when ART is available but delivered suboptimally
(i.e., few individuals enter care early, monitoring is infre-
quent, and no CD4 cell counts are taken) and with the
situation when some elements of ART delivery are improved.
Next, we looked at the impact of these strategies on the
health-care system and identiﬁed how observed trends in
survival or efﬁciency may be affected. Finally, we compared
the different monitoring (Table 1) and ART initiation
strategies (Table 2) in order to inform decisions on how
ART delivery could make best use of available resources.
Technical Specification of Model and Data Sources
The mathematical model stochastically simulates disease
progression in a cohort of 1,000 HIV-infected adults and
tracks the services they receive and key health indicator
outcomes. Each individual is realised independently and the
properties of the individual and the timing of events are
calculated probabilistically based on a series of rules and
parametric distributions. Draws from the distributions are
simulated by transforming standard uniform deviates from
the pseudorandom number generator in MATLAB software
(version 7.0.1.24704 (R14) Service Pack 1; Mathworks). The
data used to parameterise the disease-progression part of the
model were taken from several African studies, and the
composition of the model cohort was based on the age and
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Monitoring Patients before ARTsex distribution of incident HIV infections between 1998 and
2002 in eastern Zimbabwe [20]. Life expectancy in the
absence of HIV was calculated using observed mortality rates
among uninfected individuals [21].
Each individual was assigned a CD4
þ cell count after
seroconversion and a ﬁxed rate of CD4
þ cell decline [22], so
that in the cohort there was a range of fast and slow
progressors. A steady decline in the square-root of CD4
þ cell
count is theoretically [23], clinically [24], and statistically [25–
27] justiﬁed. In the model, older individuals (. 35 y) progress
to immune suppression faster than younger individuals. The
CD4
þ cell count at which an individual develops symptoms
sufﬁciently severe to seek medical attention was drawn
stochastically from a distribution based on data from clinic
attendees in Co ˆte d’Ivoire [28].
After the CD4
þ cell count reaches 200/ll, the time until
death without treatment was exponentially distributed with a
median 11 mo [29]. The median time between HIV infection
and death in the model was ;9.5 y, which is in good
agreement with independent observation [30]. The parame-
ters determining the CD4
þcell count at which clinical signs of
severe immune suppression may be detected by a trained
clinician (WHO stage 3 or 4) was based on data from Uganda
[13] and Ethiopia [14].
A range of possible points at which an individual could be
diagnosed with HIV is represented in the model. Individuals
could discover they are infected when presenting at a clinic
Table 2. Possible ART Initiation Rules Used in the Model
Rule No. Definition Number of CD4
Measurements
Decision to Initiate ART
Symptoms No Symptoms Symptoms No Symptoms
1 Syndromic initiation 0 0 Start Do not start
2 Initial CD4 measurement, thereafter symptomatic initiation 0
a 0
a Start Start if m , 200
a
3S I þ CD4 confirmation if symptomatic 1 0 Start if m , 350 Do not start
4S I þ CD4 confirmation if asymptomatic 0 1 Start Start if m , 200
5 CD4 monitoring: high blanket threshold 1 1 Start if m , 350 Start if m , 350
6 CD4 monitoring: low blanket threshold 1 1 Start if m , 200 Start if m , 200
7 WHO-CD4 recommendations 1 1 Start if m , 350 Start if m , 200
8
c WHO recommendations with 2 CD4 measurements
(take mean)
2 2 Start if m , 350 Start if m , 200
9
c WHO recommendations with 2 CD4 measurements
(take minimum)
2 2 Start if m , 350 Start if m , 200
10
c WHO recommendations with 2 CD4
measurements (take minimum) if first close
b
1–2 1–2 Start if m , 350 Start if m , 200
aNo measurement after the first appointment.
bA measurement is ‘‘close’’ if it is no more than 30 cells/ll greater than the appropriate initiation threshold.
cIf a second measurement is made, another appointment is required.
m, CD4
þ cell ount, cells/ll.
doi:10.1371/journal.pmed.0050053.t002
Table 1. Possible Monitoring Strategies for HIV-Infected Patients prior to Starting ART
Scenario CD4
þ Cell Count (m), cells/ll Time until Next Scheduled Appointment
Age at Infection , 35 Years Age at Infection   35 Years
Scenario I Any 1 y 1 y
Scenario II Any 6 mo 6 mo
Scenario III Any 3 mo 3 mo
Scenario IV m   350 3 mo 3 mo
350 , m   500 6 mo 6 mo
m . 500 1 y 1 y
Scenario V m   350 6 mo 3 mo
350 , m   500 1 y 6 mo
m . 500 2 y 1 y
Scenario VI Any 1 y 6 mo
Scenario VII Any None scheduled
a None scheduled
a
The interval until the next monitoring appointment is determined at the ‘‘current’’ monitoring appointment. The interval may depend on the CD4
þcell count measurement at the current
appointment if one is made (mi(t)), and/or the age of the patient. In all scenarios, if individuals develop symptoms of immune suppression before the next scheduled appointment, they
can attend an appointment immediately.
aPatients attend when symptoms develop.
doi:10.1371/journal.pmed.0050053.t001
PLoS Medicine | www.plosmedicine.org March 2008 | Volume 5 | Issue 3 | e53 0405
Monitoring Patients before ARTafter developing symptoms. Other individuals could ﬁnd they
are infected when tested at an ANC or attending VCT. Age-
and disease state-speciﬁc fertility rates [31–33] were used to
capture the timing of pregnancies, and two scenarios are
deﬁned for the chance that a pregnant women attends an
ANC and is referred to the ART programme: low referral rate
(10% of pregnant women) and high referral rate (90%). In
addition, VCT uptake can be low (5% of individuals receive
VCT) or high (70% receive VCT). Alternatively, the individual
may die before being diagnosed with HIV.
Once individuals are known to be infected with HIV, they
are then managed by the hypothetical ‘‘ART programme.’’
Immediately after diagnosis there was an ‘‘appointment’’ in
which the need for ART was assessed. If the individual did not
start ART at the ﬁrst appointment, another was scheduled
after a set interval; in the model there were seven possible
scenarios, labelled I to VII (Table 1). Some individuals
(selected randomly) may drop out at follow-up and not return
for further scheduled monitoring appointments. If any
patient developed symptoms before the next appointment,
they nevertheless attended another appointment immedi-
ately. Whether an individual should start ART was determined
by the initiation rule. This rule could be based on symptoms
and/or CD4
þ cell count measurements. There were nine
possible initiation rules in the model, numbered 1 to 9 (Table
2). Each measurement of the CD4
þ cell count was assumed to
be subject to random error, to reﬂect short-term physiolog-
ical variation and technical laboratory factors [34,35].
In the absence of long-term follow-up studies from low-
income settings, three sets of assumptions were made about
survival on ART termed ‘‘best’’, ‘‘medium,’’ and ‘‘worst’’.
First-year mortality was parameterised using data from the
ART-LINC collaboration of cohort studies in low-income
settings [7], with the medium scenario set by the point
estimates and the other scenarios set by the bounds of the
95% conﬁdence intervals. The relationship between CD4
þ
cell count, symptoms, and hazard of death after the ﬁrst year
was based on data from high-income settings [6]. In the ‘‘best’’
scenario, the hazard of mortality observed in the ﬁrst 3 y was
assumed to stay constant over time on ART; in the medium
scenario it increased gradually; and in the pessimistic
scenario the hazard of death increased sharply. The ‘‘me-
dium’’ scenario, which was used in simulations unless
otherwise stated, produced 4-y survival rates of ;75% for
those starting with CD4
þcell count below 50 cells/ll, and 90%
for those starting with CD4
þ cell count between 200 and 349,
which is in good agreement with longer-term analyses of the
ART-LINC cohort data [36].
Pregnant women who were in care or attended an ANC
during pregnancy were eligible to receive treatment to
prevent mother-to-child transmission if they were not already
on ART. The model was parameterised to reﬂect mother-to-
child transmission in the context of treatment using a single
dose of nevirapine, followed by 7–17 mo of breast-feeding
[37,38]. Child deaths were deﬁned as deaths before the 15th
birthday, and a child was assumed to be (maternally)
orphaned if the mother died whilst they were alive and
before the 18th birthday. The number of days that individuals
spent with symptoms (‘‘sick days’’) was used as a measure of
morbidity.
Further details of the model and data sources are given in
Text S1.
Results
The Impact of Alternative Strategies on Patient Outcomes
The model predicts that in the absence of treatment,
infected individuals will each lose, on average, ;22 y of life
(6 two standard deviations from mean over 20 stochastic runs:
21.0–23.0 y) and die aged 39 y (38.2–39.8 y) years having
experienced severe symptoms for ;800 d (750–850 d) (Table 3).
If patients are initiated on ART only when they develop
symptoms of immune suppression (syndromic initiation),
referral of infected women from ANC to the ART programme
is low, and uptake of VCT is low, then the predicted impact of
ART on these population-level indicators of mortality and
morbidity is modest (model A in Table 3). Although the lives
of those treated is extended by 6–17 y (depending upon the
effect of ART assumed), the average life-years saved among all
those infected (treated or not) is equivalent to only 2–4 y per
person. The effect of ART is limited by the failure to diagnose
many individuals and by starting treatment late when the
immune system is already weakened. Cumulative mortality in
the ﬁrst few years of infection is similar to the scenario in
which treatment is not available, because most fast pro-
gressors die without being treated, and the opportunity to
save life-years would be available only for those with
advanced disease (Figure 1A).
A CD4
þcell count can provide an early warning of immune
system depletion before symptoms develop. When a CD4
þcell
count is used to help decide when to initiate ART in the
manner recommended by WHO [5], ;50% more individuals
are started on ART and the extension of life for those treated
rises somewhat, to between 8 and 18 y (Figure 1B; model B in
Table 3).
Our model shows that the frequency with which patients
are monitored also determines the impact of ART (Figure 1C;
model C in Table 3). With more frequent monitoring there is
a better chance that ART can be started at the right time. In
model simulations with the same initiation rule, patients who
are monitored every 3 mo instead of every 12 mo (and attend
all scheduled appointments) are expected to live approx-
imately 1 y longer on treatment (Table 3), but this outcome
would also depend on the route through which individuals
entered care (Figure A in Text S1).
The effect of the ART delivery programme is further
improved if referral from ANC and uptake of VCT is
improved so that more individuals are diagnosed and
monitored earlier in the course of infection (Figure 1D;
model D in Table 3). The model predicts that with high levels
of referral from ANC and VCT uptake, ;80% of HIV-
infected individuals would enter care. In this scenario, the
total number of life-years saved is almost double that when
referral is low. With earlier diagnosis of infection, there are
also fewer sick days because clinical signs can be used to
initiate ART promptly.
Increasing opportunities for early diagnosis has two
beneﬁts: ﬁrst, it allows more people to enter care and receive
ART before they die; and second, it increases the chance that
ART can be initiated at the right time. To isolate the second
effect, alternative cohorts are compared in which either all
individuals enter care through referral (from ANC or VCT) or
individuals can enter care only by presenting at a clinic with
symptoms. With referral, the CD4
þ cell count at which ART is
started tends to be higher (mean 33 cells/ll), which leads to
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(Figure B in Text S1). Referral of women from ANC is
especially productive because they are typically young and
disease-free (Figure C[a] in Text S1).
Altogether, these three factors—the timing with which ART
is initiated, the opportunities for early diagnosis of infection,
and the frequency with which patients in care are monitored
(without drop-out)—combine to determine the improvement
in life expectancy at infection due to the availability of ART
(Figure 2). Upgrading from syndromic initiation with low
ANC referral rates, low VCT uptake, scheduled monitoring
every 12 mo, and 15% of patients dropping out each year,
allow ;60% more individuals to enter care, almost twice as
many entering care to be started on ART; furthermore,
individuals on ART have longer survival (up from 6 y to 15 y)
(Figure D in Text S1). This improvement leads to three times
as many HIV-infected individuals starting treatment. In total,
this could mean that life expectancy at infection by could be
increased from 10 y with no ART (worst-case), to 12–14 y with
suboptimal delivery of ART (medium), up to 17–27 y with this
‘‘best-case’’ ART delivery scenario (ranges due to different
survival assumptions). The impact of intermediate scenarios
for VCT uptake and ANC referral rates were also investigated
(Table A in Text S1).
Impact on the Health-Care System
When more individuals are diagnosed and diagnosed at an
earlier stage, the case load for the ART programme is higher
(Table 3). The average difference between the worst- and
best-case scenarios described above is 14 more appointments
per person infected, 19 CD4
þ cell counts taken per person
diagnosed, and 10 y more on ART, per person infected (Table
3). It is therefore essential to implement strategies that
maximise patient outcomes whilst minimising costs (years of
therapy and time of health-care workers). Recommendations
for how this can be done are made in the following section.
However, the model does identify complicating factors in
measuring the performance of programmes that should be
considered. First, the apparent effectiveness of ART at the
population level may not improve when more individuals are
diagnosed earlier through VCT (Figure C[b] in Text S1).
Those progressing to AIDS fastest, who would otherwise die
outside of the ART programme, will start ART when already
immune suppressed and die within the programme, bringing
down measures such as average survival time on ART. Second,
the number of life-years saved per year on ART may decrease
if infections are diagnosed earlier, because some patients
would start ART too soon (due to random error in CD4
þ cell
measurement or early symptoms), but would otherwise have
survived for some years more without treatment. Other
patients would enter care who are at an early stage of
infection or are ‘‘slow progressors,’’ and these individuals
would be monitored unnecessarily for many years.
Implications for Resource-Poor Settings
Alternative strategies for ART initiation and patient
management (Tables 1 and 2) were investigated. In these
simulations we assumed a 5% yearly drop-out rate during
follow-up, but the qualitative relationship between the
strategies investigated was not inﬂuenced by this assumption.
Table 3. Key Indicator Outcomes for Alternative Initiation Decision Rules and Health-Care System Parameters
Measure, per
1,000 Infected
No
Treatment
ART Effect, Model A ART Effect, Model B ART Effect, Model C ART Effect, Model D
Worst Medium Best Worst Medium Best Worst Medium Best Worst Medium Best
Person-years lost to
HIV/AIDS (1,000s)
22 21 19 18 19 17 15 18 15 13 16 10 6
Mean age at death, y 39 41 42 44 42 44 46 43 46 48 46 51 55
Number of ‘‘sick days’’
(1,000s)
798 603 578 568 631 614 589 588 561 543 381 335 287
Number of child
deaths (,15 y)
175 175 172 176 169 177 172 175 173 173 165 171 172
Number of maternal
orphanings
305 297 270 254 283 248 221 270 209 182 233 129 86
Life-years saved (1,000s) n/a 1.5 2.9 4.2 2.8 5.0 6.6 4.0 7.3 9.4 6.5 12.1 15.7
Years on ART (1,000s) n/a 2.1 3.5 4.8 3.5 5.7 7.3 5.2 8.4 10.6 8.6 14.2 17.9
Percent ever diagnosed n/a 51 51 50 51 51 51 51 51 51 82 81 82
Number of monitoring
appointments (1,000s)
n/a 1.6 1.6 1.6 1.5 1.5 1.5 6.0 5.9 6.0 15.6 15.8 16.0
CD4 tests per person
diagnosed
n/a 0 0 0 3 3 3 12 12 12 19 19 20
Number treated n/a 250 246 247 370 370 362 495 494 495 788 785 792
Life-years saved per
person diagnosed
n/a 3.0 5.8 8.4 5.5 9.8 13.0 7.9 14.3 18.4 7.9 14.8 19.2
Years on ART per
person treated
n/a 8.6 14.4 19.6 9.5 15.5 20.3 10.4 17.0 21.3 10.9 18.1 22.6
Life-years saved per
person treated
n/a 6.0 11.9 17.1 7.5 13.5 18.2 8.1 14.7 19.0 8.2 15.4 19.9
Model A: syndromic initiation; monitoring every 12 mo; 15% drop-out at follow-up; low ANC referral; low VCT uptake.
Model B: WHO-CD4 initiation; monitoring every 12 mo; 15% drop-out at follow-up; low ANC referral; low VCT uptake.
Model C: WHO-CD4 initiation; monitoring every 3 mo; no drop-out at follow-up; low ANC referral; low VCT uptake.
Model D: WHO-CD4 initiation; monitoring every 3 mo; no drop-out at follow-up; high ANC referral; high VCT uptake.
n/a, not applicable.
doi:10.1371/journal.pmed.0050053.t003
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clear advantage in using CD4
þ cell counts to check that
asymptomatic individuals are not severely immune sup-
pressed (Figure 3: rules 1–3 versus 4–10). Using only one
CD4 measurement (taken at the ﬁrst monitoring appoint-
ment) enables substantially more life-years to be saved than
does syndromic management alone (rule 2 versus rule 1). The
alternative strategies of testing everyone (rule 7), and testing
only those without symptoms (rule 4) are similarly effective,
although the latter requires ;10% fewer CD4 measurements
(Table B in Text S1). If treatment is initiated at higher CD4
þ
cell levels than WHO recommends (rule 5), more life-years
are saved but this timing requires disproportionately more
years on ART (years on ART per life-year saved: 1.20 versus
1.17), because many individuals would survive for years after
reaching this threshold without ART. The opposite is true if
ART is used more selectively by initiating at lower CD4 levels
(rule 6); here, fewer life-years are saved but many fewer years
are spent on ART (years on ART per life-year saved, 1.11 y).
When all strategies are compared, those that use more CD4
measurements tend to save more life-years overall and more
life-years per year on ART. The advantage of CD4
þcell counts
is greater when the association between CD4 level and
symptoms is weak (Figure E in Text S1). However, the model
suggests that CD4
þ cell counts remains advantageous under a
variety of scenarios for this relationship (Figure E in Text S1).
The physiological variability of CD4
þ cell counts means
that taking two measurements instead of one could lead to
better clinical decision-making for individuals. However, in
the model, basing clinical decisions on the mean of two
measurements does not lead to substantial improvements,
because it is assumed that measurement errors are equally
likely to lead to earlier initiation as to later initiation (Figure
3: rule 8). Basing the decision on the minimum of two
measurements, in contrast, does increase the chance of ART
initiation, and more life-years are saved without a substantial
increase in years spent on ART (Figure 3: rule 9). If all
patients have two CD4
þ cell measurements, twice as many
monitoring appointments and CD4
þ cell counts are required,
but if a second CD4
þ cell count is taken only when the ﬁrst is
just above the initiation threshold (within 30 cells/ll), then
fewer tests are required per life-years saved (Figure 3: rule 10;
Figure F in Text S1).
With more frequent monitoring, the chosen ART initiation
strategy can be implemented more accurately and more life-
years can be saved (Figure G[a] in Text S1). For the same
reason, drop-out from follow-up appointments (patient not
attending the next scheduled appointment) can result in
substantial reductions in the impact of ART programmes
(Figure G[b] in Text S1). Scheduling appointments is essential
because relying on individuals to attend only when they
experience symptoms defeats the advantages of early diag-
nosis. Infrequent monitoring and/or high drop-out rates are
particularly damaging to programmes using CD4
þ cell counts
because these factors increase the chance that patients are
not monitored as they cross the threshold for ART initiation
(Figure G in Text S1).
An efﬁcient allocation of appointments is to schedule
Figure 1. Survival Distribution of an Infected Cohort in Different Models
Solid black line, no treatment is available. Where treatment is available, the blue line indicates that ART is available and its assumed effect is worst, the
green line indicates a middle effect, and a red line indicates the effect is the best. The survival of an age and gender-matched cohort that is not infected
is shown for comparison (dashed black line). The parameterisations of the ART programmes are the same as in Table 3: (A) Syndromic initiation (rule 1),
monitored every 12 mo, 15% drop-out, low ANC referral, and low VCT uptake; (B) CD4 initiation (rule 7), monitored every 12 mo, 15% drop-out, low ANC
referral, low VCT uptake; (C) CD4 initiation; monitored every 3 mo, no drop-out; low ANC referral, and low VCT uptake; (D) CD4 initiation, monitored
every 3 mo, no drop-out, high ANC referral, and high VCT uptake.
doi:10.1371/journal.pmed.0050053.g001
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þ cell counts to be monitored less
frequently than those with low CD4
þ cell counts (scenario IV)
(Figure H in Text S1). The model predicts that in this system,
there would be 50% more appointments than if everyone
were monitored every 12 mo, but this increase would lead to
2.1 more life-years saved per person diagnosed (Figure H in
Text S1). The number of appointments is reduced further
without a substantial reduction in the life-years saved if the
scheduling system also takes account of age (scenario V),
where young people are monitored less frequently than older
(35þ y) people.
Discussion
There is great potential for ART to reduce premature
deaths due to AIDS in resource-poor settings, but inadequate
monitoring of HIV-infected individuals not on treatment
could prevent this potential from being fully realised. Our
modelling shows that using CD4
þ cell counts to determine
when to initiate ART could greatly increase the number of
life-years saved, because it enables individuals to receive ART
when the effect of therapy is greatest, before the immune
system is severely weakened [6,7]. New CD4
þ cell counting
technology is more affordable and better suited to conditions
with limited health-care infrastructure [39–41], and in the ‘‘3
by 5’’ program (the campaign to get 3 million on therapy by
2005) most of the resource-limited focus countries used CD4
þ
cell counts to help judge when ART should be initiated [42].
However, since individuals tend to present at clinics with
advanced disease [28], the ART programme must be
competent at ﬁnding individuals at earlier stages. Regularly
monitoring patients can further improve their prognosis
because it increases the chance that ART can be started at the
right time. Although HIV testing services are being rapidly
scaled-up, currently only 8%–25% of those infected have
discovered that are living with HIV [43]. However, the
movement towards provider-initiated testing [44] is expected
to lead to great increases in diagnosis of HIV infections. In
Botswana, where a similar policy was implemented in 2004,
almost half of a general population sample reported having
had an HIV test [45]. Referring women who have tested
positive at ANCs is expected to be especially productive,
because they are likely to be young and at an early stage of
disease.
The CD4
þ cell count is a more sensitive indication of need
for ART than the presence of symptoms, so CD4
þ cell count-
based initiation is expected to enable more life-years to be
saved and more life-years saved per year of therapy. The
model shows that even making just one CD4 measurement at
the ﬁrst appointment, to catch those in need at ART when
they ﬁrst enter care, is likely to improve the impact of the
programme substantially. Testing at every appointment, and
Figure 2. Improvements in Life Expectancy at Infection Due to the Availability of ART
In (A) only symptoms are used to initiate ART (rule 1); in (B) one CD4
þ cell count measurement is used in the way WHO recommend (rule 7). In both
panels, 5% yearly drop-out rate is assumed.
doi:10.1371/journal.pmed.0050053.g002
Figure 3. Comparison of Possible Initiation Rules in Years Saved per
Person Diagnosed
Appointments are scheduled for every 6 mo. Error bars show 6 2
standard deviations from 20 stochastic runs. 5% yearly drop-out rate is
assumed. Details of rules are listed in Table 2.
doi:10.1371/journal.pmed.0050053.g003
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cases, maximise the usefulness of the available CD4
þ cell
count information. Routinely starting patients with higher
CD4
þ cell counts than the WHO recommends would save
more life-years overall, but fewer life-years per years on
therapy. Avoiding CD4
þ cell counts for those who have
already developed symptoms could reduce the number of
counts required without sacriﬁcing impact, because few
symptomatic individuals will have a CD4
þ cell count higher
than 350 cells/ll.
The efﬁciency of appointment scheduling can be improved
by prioritising the more immune suppressed (CD4
þcell count
  350) and older (35þ y) patients, since they probably need
ART sooner. Relying on individuals to return to the clinic
when they develop symptoms would reduce the number of
appointments required, but is not an effective way to manage
patients; symptoms unreliably predict the need for ART.
This model analysis shows that increases in rates of patient
referral, earlier and more frequent monitoring of HIV-
infected patients, and better rules for initiating ART could
lead to increases in the number of appointments with ART
providers and the amount of ART required. By evaluating the
cost of providing these services, a cost-effectiveness study
could determine, for a speciﬁc location, which of these
changes would lead to the most efﬁcient allocation of
resources [46]. Without considering the costs involved, it is
not possible to make speciﬁc recommendations about the
optimal method for managing patients.
The substantial differences in expected ART outcomes for
different programmes and modes of patient management
should lead, over time, to large differences in the number in
need of therapy. Projections of ART requirements will
therefore need to examine how ART is initiated and how
patterns of diagnosis and referral could change. Current
estimates that are based on calculating the fraction of
infected individuals in the last few years before death do
not take the variation in strategies or their evolution over
time into consideration [38,47,48].
The model is limited by a lack of data on the relationship
between the WHO staging criteria and CD4
þcell count, which
underlies the quantitative estimates of the beneﬁt of different
types of initiation. Although the average CD4
þ cell count
among patients with certain conditions has been reported in
several studies [11,12,49], it is not possible to know which of
these patients a clinician would determine to be in need of
ART. The data we have used to parameterise the model
suggest that many individuals with low CD4
þ cell count would
not be categorized as appropriate for ART under WHO
guidelines [13,14]. However, our analysis indicates that
monitoring CD4
þ cell counts remains generally advisable
under a wide range of scenarios for this relationship,
including the development of symptoms before severe
immune suppression in the majority of people (Figure E in
Text S1).
In the absence of more detailed data, the model does not
differentiate between WHO stage 3 and 4 disease and cannot
replicate the clinical judgement that should be used to
determine how soon patients with stage 3 symptoms should
be started on ART [5]. Instead it identiﬁes individuals who
develop ‘‘severe symptoms of immune suppression’’ that are
analogous to WHO stage 3, and we explore the effects of
using different CD4
þ cell count thresholds for starting ART.
Under the WHO recommendations, patients with stage 4
symptoms should be started on ART regardless of their CD4
level, but in the model they are started only if their CD4
þ cell
count falls below the threshold being used for starting any
symptomatic patient. However, patients with stage 4 disease
seldom have higher CD4
þ cell counts than this, so the model
will only slightly underestimate the impact of following the
WHO guidelines.
A public-health approach to delivering ART has to
consider how to initiate ART and organise the delivery
programme to maximise the beneﬁt to the population
overall. According to this model, diagnosing infections earlier
(through referrals from ANC or VCT), regularly monitoring
patients, and using CD4
þ cell counts to initiate ART will save
more life-years. Unless this care is available to patients at all
stages of HIV infection, the long-awaited chance to substan-
tially reduce AIDS mortality with ART could fall far short of
its full potential.
Supporting Information
Text S1. Extended Methods Section and Further Results
Found at doi:10.1371/journal.pmed.0050053.sd001 (274 KB PDF).
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Background. Acquired immunodeficiency syndrome (AIDS) has killed
more than 25 million people since the first case in 1981, and about 33
million people are currently infected with the human immunodeficiency
virus (HIV), which causes AIDS. HIV destroys immune system cells
(including CD4 cells, a type of lymphocyte), leaving infected individuals
susceptible to other infections. Early in the AIDS epidemic, most HIV-
positive individuals died within 10 years but in 1996, combination
antiretroviral therapy (ART)—a mixture of powerful but expensive
antiretroviral drugs—was developed. For HIV-positive people living in
affluent, developed countries who could afford ART, AIDS then became a
chronic disease, but for those living in low- and middle-income countries
it remained a death sentence—ART was too expensive. In 2003, this lack
of access to ART was declared a global health emergency and
governments, international organizations, and funding bodies began
to implement plans to increase ART coverage in developing countries.
Why Was This Study Done? The roll-out of ART in developing countries
has concentrated so far on finding HIV-positive people who currently
need treatment. In developing countries, these are often individuals who
have AIDS-related symptoms such as recurrent severe bacterial
infections. But healthy people are also being diagnosed as HIV positive
during voluntary testing and at antenatal clinics. How should these HIV-
positive but symptom-free individuals be managed? Should regular
health-monitoring appointments be scheduled for them and when
should ART be initiated? Management decisions like these will determine
how well patients do when they eventually start ART, as well as the
demand for ART and other health-care services. The full range of
alternative patient management strategies cannot be tested in clinical
trials—it would be unethical—but public-health officials need an idea of
their relative effectiveness in order to use limited resources wisely. In this
study, therefore, the researchers use mathematical modeling to
investigate the impact of alternative patient management and ART
initiation strategies on the impact of ART programs in resource-poor
settings.
What Did the Researchers Do and Find? The researchers’ mathematical
model, which includes data on disease progression collected in Africa,
simulates disease progression in a group (cohort) of 1,000 HIV-infected
adults. It tracks these individuals from infection, through diagnosis and
clinical monitoring, and into treatment and predicts how many will
receive ART and their length of survival under different management
scenarios and ART initiation rules. The model predicts that if HIV-positive
individuals receive ART only when they have AIDS-related symptoms,
only a quarter of them will ever start ART and the average life-years
saved per person treated will be 6 years (that is, they will live 6 years
longer than they would have done without treatment). If individuals are
recruited to ART programs when they are healthy and are frequently
monitored using CD4 cell counts to decide when to start ART, three-
quarters of the cohort will be treated and 15 life-years will be saved per
person treated. The impact of ART programs will be increased further,
the model predicts, by preferentially monitoring people who are more
than 35 years old and the most immunosuppressed individuals. Finally,
strategies that measure CD4 cells frequently will save more life-years
because ART is more likely to be started before the immune system is
irreversibly damaged. Importantly for resource-poor settings, these
strategies also save more life-years per year on ART.
What Do These Findings Mean? As with all mathematical models, the
accuracy of these predictions depends on the assumptions built into the
model and the reliability of the data fed into it. Also, this model does not
estimate the costs of the various management options, something that
will need to be done to ensure effective allocation of limited resources.
Nevertheless, these findings provide several general clues about how
ART programs should be implemented in poor countries to maximize
their effects. Early diagnosis of infections, regular monitoring of patients,
and using CD4 cell counts to decide when to initiate ART should all help
to improve the number of life-years saved by ART. In other words, the
researchers conclude, effectively managing individuals at all stages of
HIV infection is essential to maximize the impact of ART.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/doi:10.1371/journal.pmed.
0050053.
  Information from the US National Institute of Allergy and Infectious
Diseases on HIV infection and AIDS.
  Information from the US Centers for Disease Control and Prevention
on global HIV/AIDS topics (in English and Spanish)
  HIV InSite, comprehensive and up-to-date information on all aspects of
HIV/AIDS from the University of California, San Francisco
  Information from Avert, an international AIDS charity, on HIV and AIDS
in Africa and on HIV/AIDS treatment and care, including universal
access to ART
  Progress toward universal access to HIV/AIDS treatment, the latest
report from the World Health Organization (available in several
languages)
  Guidelines for antiretroviral therapy in adults and adolescents are
provided by the World Health Organization and by the US Department
of Health and Human Services
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